Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Return on Equity (2017 - 2025)

Vistagen Therapeutics' Return on Equity history spans 8 years, with the latest figure at 1.14% for Q4 2025.

  • For Q4 2025, Return on Equity fell 73.0% year-over-year to 1.14%; the TTM value through Dec 2025 reached 1.14%, down 73.0%, while the annual FY2025 figure was 0.56%, N/A changed from the prior year.
  • Return on Equity for Q4 2025 was 1.14% at Vistagen Therapeutics, down from 1.01% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.15% in Q1 2024 and bottomed at 1.73% in Q3 2023.
  • The 4-year median for Return on Equity is 0.41% (2024), against an average of 0.6%.
  • The largest annual shift saw Return on Equity tumbled -2292bps in 2021 before it skyrocketed 145bps in 2024.
  • A 4-year view of Return on Equity shows it stood at 0.46% in 2021, then increased by 18bps to 0.38% in 2023, then decreased by -8bps to 0.41% in 2024, then tumbled by -176bps to 1.14% in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Return on Equity are 1.14% (Q4 2025), 1.01% (Q3 2025), and 0.88% (Q2 2025).